|
Management
Primorigen Biosciences was founded by Chuck Oehler, Chairman and President, and Dr. Thomas Burke, CEO.
Dr. Burke was Co-founder, Chief Scientific Officer, and Executive Vice President of PanVera Corporation, which was started in Madison, WI 1992 and grew to $20 M. in sales on just $4 M. in invested capital before being sold in 2001 to Aurora Biosciences. He previously was Director of Manufacturing and co-developed many top-selling products for Promega Corporation, a major worldwide life sciences research products firm. He also served on the Board of Directors for Gentel Biosciences, Inc. and on several scientific advisory boards for companies such as Gentel Biosciences, Quintessence Biosciences, and EMD Biosciences. He is currently on the investment board of Kegonsa Capital Partners, a venture capital seed fund, and is on the Investment Advisory Board for Madison Development Corporation. Dr. Burke was an adjunct professor at the University of Wisconsin Medical School and taught for three years in the Masters in Biotechnology Program; he still maintains a part-time affiliation with this University program
Mr. Oehler was a Vice President of Promega Corporation, where he built a multi-million dollar, revenue-generating research funding program and led the company's business and corporate development functions. He subsequently founded The Oehler Group, a consulting practice that has assisted leading biotechnology firms throughout the U.S. in raising nearly $30 M. for research and development, and in obtaining new business partnerships. In 2004, he co-founded NuPotential LLC, a biotechnology firm focused on developing novel cell reprogramming technologies that has won substantial NIH funding support. He also built the Wisconsin Biotechnology Association to over 100 companies as elected President and consulting Executive Director, and founded the WBA Midwest Regional Biotechnology Conference and other lucrative new profit centers for the Association. His many industry leadership roles have included service with Governor Tommy Thompson's Council on Biotechnology, the UW Medical School Biotechnology Master's Degree Program Board, the first BIO National Grassroots meeting, the 2004 Great Lakes Biomedical Conference, and others.
Dr. William Patterson, Senior Director, R&D, leads Primorigen's quantitative microarray product development program. Dr. Patterson formerly served as microarray product development group leader at Pierce Biotechnology of Fisher Scientific, a multi-billion dollar life sciences research products company. Prior to his tenure with Pierce, Dr. Patterson held a similar position at Promega Corporation.
Dr. Nicholas Caruccio, Director of Marketing, previously led Invitrogen Corporation’s protein contract services, significantly growing top line revenue and increasing on time delivery. Prior to that, he was Production Supervisor for protein purification at Promega Corporation, managing the manufacture and QC testing of the antibody and signal transduction product groups.
Ms. Jennifer Fronczak, Operations Manager, manages Primorigen's laboratory and production operations. Ms Fronczak has experience at both early stage (Bellbrook Labs) and large research products firms (Invitrogen Corporation) in developing protocols for production, quality assurance, shipping and related functions, and in actual manufacturing and product support.
Primorigen's growing scientific capabilities is providing customers with standard, ready-to-use products, and customized services to address customers' unique requirements for product development and contract research and production.
|
